Health Care · Biological Products, (No Diagnostic Substances)

TARA Protara Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1359931115 filings
Russell 2000

TARA at a glance

Protara Therapeutics, Inc. (TARA, SEC CIK 1359931) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 6, 2026 and Form 4 insider filings as recently as July 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Protara Therapeutics, Inc. (TARA) shares worth $60.5 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Shefferman Jesse on June 29, 2026 of 215,687 shares at $4.09 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
26 funds
$60.5M · −2 vs prior quarter
Latest 8-K
Nov 6, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no product sales since inception
  • Operating margin not meaningful: operating loss $23.2M vs $14.8M YoY
  • R&D highest spend, $16.8M vs $9.6M, led by NMIBC expenses of $6.9M
  • Cash and securities $143.1M vs $197.9M at December 31, 2025; operating cash use $55.2M
  • ADVANCED-2 enrollment expected complete by end of 2026; interim THRIVE-3 results expected fourth quarter 2026

Risk Factors

  • No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
  • Carried-forward risks remain applicable across regulatory, operational, competitive, and financial categories

AI summary of the TARA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Protara announced financial results for the quarter ended September 30, 2026
  • Full results and management commentary are in Exhibit 99.1, the accompanying earnings release

Item EX-99.1: Item EX-99.1

  • TARA-002 NMIBC enrollment targeted for Q4 2026, a key catalyst for registrational ADVANCED-2 progress
  • STARBORN-1 LM enrollment pushed to early Q1 2027, with rolling BLA submission still planned for 2H 2027
Filed Aug 11, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Cash, cash equivalents and investments $161.9M at June 30, 2026, expected to fund operations into 2028
  • ADVANCED-2 BCG-unresponsive enrollment targeted for 4Q 2026, a key NMIBC registrational milestone

Item 2.02: Results of Operations and Financial Condition

  • Protara announced financial results for the quarter ended June 30, 2026
  • Detailed results and management commentary are contained in Exhibit 99.1, the attached press release
Filed Jun 29, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Chief Medical Officer Leonardo Viana Nicacio resigned effective June 26, 2026 to pursue other opportunities
  • Medical leadership responsibilities transferred to Lead Medical Director Carla Beckham

AI summaries of TARA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TARA

Don't miss the next TARA filing

  • Alerts as it files. A push when TARA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TARA, by share count.
  • Ask anything. An AI agent that reads every TARA filing and answers with sources.

TARA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Shefferman JesseGJun 30, 2026-
Shefferman JesseGJun 30, 2026-
Shefferman JesseGJun 30, 2026-
Shefferman JesseGJun 30, 2026-
Shefferman JesseMJun 29, 2026$1.91
Shefferman JesseSellJun 29, 2026$4.09
Shefferman JesseMJun 29, 2026-
BESHAR LUKE MAJun 15, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$43.6M-$49.2M-$64.5M
Net Income-$40.4M-$44.6M-$57.4M
Balance Sheet
Total Assets-$181.5M$209.5M
Equity$68.3M$167.1M$196.4M
ROE-59.2%-26.7%-29.2%
Per Share
EPS$-3.57$-2.17$-1.34
Cash Flow
Operating CF-$37.6M-$35.8M-$56.4M
CapEx$45K$63K$94K

Source: XBRL data in Protara Therapeutics, Inc. (TARA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TARA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TARA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$60.5M
Q2 202628$70.3M
Q1 202626$86.8M
Q4 202525$58.4M
Q3 202523$38.2M
Q2 202521$25.2M
Q1 202514$22.9M
Q4 202411$25.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 174 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TARA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 6, 2026Analysis
8-KNov 6, 2026Analysis-
10-QAug 11, 2026Analysis
8-KAug 11, 2026Analysis-
4Jul 1, 2026--
8-KJun 29, 2026Analysis-
4Jun 16, 2026--
4Jun 16, 2026--
4Jun 16, 2026--
4Jun 16, 2026--
4Jun 16, 2026--
4Jun 16, 2026--
4Jun 16, 2026--
4Jun 16, 2026--
8-KJun 15, 2026Analysis-
8-KMay 13, 2026Analysis
10-QMay 13, 2026Analysis
SC 13GApr 27, 2026-
4Apr 9, 2026--
4Apr 2, 2026--
8-KMar 30, 2026--
10-KMar 10, 2026-
8-KMar 10, 2026Analysis-
SC 13GMar 2, 2026-
8-KFeb 24, 2026Analysis-

Related Health Care companies

All Health Care →

TARA SEC filings: frequently asked questions

Which institutions hold TARA stock?

As of September 30, 2026, the largest Protara Therapeutics, Inc. (TARA) holders among the 13F filers tracked by SignalX were BlackRock ($11.3 million), Millennium Management ($9.4 million), Blackstone Group ($7.2 million), Vanguard Capital Management LLC ($7.0 million), Citadel Advisors LLC ($6.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did TARA report in its latest 8-K?

Protara Therapeutics, Inc. (TARA) filed an 8-K on November 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Protara announced financial results for the quarter ended September 30, 2026.

What are the latest TARA SEC filings?

Protara Therapeutics, Inc. (TARA) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 6, 2026 and a Form 4 insider filing on July 1, 2026.

What is TARA's SEC CIK number?

Protara Therapeutics, Inc. (TARA)'s SEC Central Index Key (CIK) is 1359931. EDGAR lists every TARA filing under that number.

Ask anything about TARA

The research agent reads TARA's filings, financials, insider trades and 13F holders, then answers with sources.